Scope Fluidics SA
GGPW:SCP130.60
PLN
-2.60
(-1.95%)
ISIN
PLSCPFL00018
Return %
Stock
S&P 500
1Y
-25.20
14.20
3Y
-19.38
81.12
5Y
-8.29
68.34
Capital Structure
PLN
•
in mil. unless spec.Working Capital
PLN
•
in mil. unless spec.Growth Rates
PLN
•
in mil. unless spec.Quarterly Revenue
PLN
•
in mil. unless spec.Quarterly Earnings Per Share
PLN
•
in mil. unless spec.Quarterly Dividends Per Share
PLN
•
in mil. unless spec.Company Description
- CEO
- Piotr Garstecki
- Full Time Employees
- 157
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- Ogrodowa 58 Street Warsaw MZ Poland 00-876
- IPO Date
- Aug 16, 2017
- Website
- scopefluidics.com
- Similar Companies
- Business
- Scope Fluidics S.A. is a biotechnology company specializing in the design and development of innovative medical diagnostics and healthcare projects based on microfluidic technologies. Established in 2010 and headquartered in Warsaw, Poland, the company operates through a unique business model that involves creating and advancing projects within special-purpose vehicles (SPVs) before selling them to global entities. Its main product offerings include the BacterOMIC system, which is an advanced diagnostic device designed to assess the drug susceptibility of microorganisms, thereby addressing antibiotic resistance challenges. Additionally, the company is developing the PCR|ONE system, a technology for rapid and automated detection of bacterial and viral infections through highly multiplexed PCR assays. Scope Fluidics targets fast, effective, and accessible medical diagnostics aimed at improving treatment quality and reducing time and costs associated with hospitalization. In the last 1-2 years, Scope Fluidics has notably expanded its project portfolio with the establishment of new SPVs, including BacterOMIC, targeted for European market entry within 2025, and two additional projects named EDOCERA and HYBOLIC, which are in advanced development phases. The company is intensifying investments in these projects aiming to secure IVDR and FDA certifications and scale production capabilities to enable commercial sales. Significant strategic moves include divesting its subsidiary Curiosity Diagnostics for USD 130 million and focusing on scaling and commercializing innovative diagnostic solutions. Scope Fluidics also plans to expand its financing options by issuing new shares to support ongoing project development and market scaling efforts. It maintains strong scientific and operational teams and a quality management system to protect intellectual property and foster innovation. Scope Fluidics operates primarily in the biotechnology, diagnostics, and med-tech industry sectors within Poland but focuses on developing solutions for global markets. The company’s customer base includes healthcare providers and institutions requiring rapid diagnostics for bacterial infection susceptibility and pathogen detection. Scope Fluidics’ unique project incubation through SPVs and its track record of technology sales and development position it as an innovator in microfluidic-based diagnostic technologies targeting critical healthcare challenges worldwide. This comprehensive approach leverages partnerships, specialized teams, and robust funding strategies to drive forward new med-tech solutions while aiming for certification and commercialization milestones that ensure global reach and impact. The company remains focused on high-value diagnostic technologies and expanding its product-range pipeline through ongoing innovation and strategic financial planning.